Clinical trials: Skin to Skin
Psoriasis
Study to Test the Effectiveness of a New Treatment for Scalp Psoriasis
The purpose of this study is to test the effectiveness of DermiPsor's DPS-102 (test product) in patients with scalp Psoroasis. The study is also intended to assess the safety of the product.
- Trial name
- NCT01368887
- Testing
- DPS-102, Calcipotriol Monotherapy, Nicotinamide Monotherapy
- Where
- 2 sites in United States
- Volunteers
- 160 people
- Sponsor
- DermiPsor, Ltd.
Rheumatoid Arthritis
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose CFZ533 in Rheumatoid Arthritis Patients
This is a first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single intravenous and subcutaneous doses of CFZ533 in healthy subjects and intravenous doses in rheumatoid…
- Trial name
- NCT02089087
- Testing
- CFZ533
- Where
- 6 sites in United States, Taiwan
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Plaque Psoriasis, Psoriasis
Study Evaluating Etanercept for the Treatment of Moderate to Severe Psoriasis
The purpose of this study is to compare the safety and efficacy of different doses of etanercept for the treatment of moderate to severe psoriasis.
- Trial name
- PRISTINE (NCT00663052)
- Testing
- Etanercept
- Where
- 38 sites in Argentina, Austria and 11 more
- Volunteers
- 273 people
- Sponsor
- Pfizer
Pain
S-Caine™ Peel (Skin Numbing Cream) to Treat Pain During Non-Ablative Facial Laser Resurfacing in Adults
Lasers are used for non-ablative resurfacing of facial rhytides, atrophic scars, and a variety of epidermal and dermal lesions. Pain associated with the non-ablative laser treatment has been described as moderate to severe.
- Trial name
- NCT00110747
- Testing
- S-Caine™ Peel (lidocaine and tetracaine topical cream 7%/7%)
- Where
- 3 sites in United States
- Volunteers
- 54 people
- Sponsor
- ZARS Pharma Inc.
Rheumatoid Arthritis, Arthritis
A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis
The main purpose of this study is to assess the safety and efficacy of peresolimab in adult participants with moderately-to-severely active rheumatoid arthritis.
- Conditions
- Rheumatoid Arthritis, Arthritis, Joint Diseases, Musculoskeletal Diseases
- Trial name
- RESOLUTION-1 (NCT05516758)
- Testing
- Peresolimab
- Where
- 131 sites in United States, Argentina and 9 more
- Volunteers
- 491 people
- Sponsor
- Eli Lilly and Company
Psoriasis
A Study of BMS-582949 in Patients With Moderate to Severe Plaque Psoriasis
The purpose of this clinical research study is to learn if BMS-582949 alone is an effective treatment for moderate to severe psoriasis. The safety of the drug and the effectiveness of each dose will also be studied.
- Trial name
- NCT00399906
- Testing
- BMS-582949
- Where
- 21 sites in Australia, Canada and 1 more
- Volunteers
- 99 people
- Sponsor
- Bristol-Myers Squibb
Androgenetic Alopecia
Safety and Efficacy Study of Human Autologous Hair Follicle Cells to Treat Androgenetic Alopecia
The primary purpose of this study is to assess the safety of performing injections of human autologous hair follicle cells. The study will also measure the impact these injections will have on hair growth.
- Trial name
- NCT01286649
- Testing
- Human autologous hair follicle cells, Cell medium
- Where
- Georgia
- Volunteers
- 19 people
- Sponsor
- TrichoScience Innovations, Inc.
Chronic Spontaneous Urticaria
A Study of Single Dose of LP-003 in Healthy Adult Subjects
The purpose of this study is to evaluate safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of LP-003 in healthy subjects.
- Trial name
- NCT06604949
- Testing
- LP-003 200mg
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Longbio Pharma
Dermatitis Atopic
A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis
This is a parallel, Phase 2b, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy, safety, and tolerability of lunsekimig monotherapy in adult participants (aged 18 to 80 years, inclusive) with…
- Trial name
- NCT06790121
- Testing
- Lunsekimig
- Where
- 52 sites in United States, Czechia and 2 more
- Volunteers
- 150 people
- Sponsor
- Sanofi
Sin Health, Skin Hydration
Clinical Study to Evaluate the Impact of aKwa Skincare System on Skin Health
The purpose of the study was to evaluate the effectiveness of the äKwä 6-step skincare system by measuring skin moisture level, fine lines and wrinkles, porphyrin count, red spots, and red vasculature counts over a 30-day period.
- Conditions
- Sin Health, Skin Hydration, Skin Wrinkles, Skin Porphyrins
- Trial name
- NCT05476406
- Testing
- äKwä skincare system products, competitor products (control)
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- 4Life Research, LLC
Acne Vulgaris
Compare the Tolerance of Clindamycin 1% /Benzoyl Peroxide (BPO) 5% Gel to Clindamycin 1.2%/ BPO 2.5% Topical Medications
This is a single-blind (blinded expert grader) study that will enroll 25-30 healthy volunteers without facial acne. On 1 side of the face, the subject will apply 1 of the 2 test products, clindamycin and benzoyl peroxide 5% or…
- Trial name
- NCT01015638
- Testing
- Clindamycin and BPO 5% gel, Clindamycin phosphate and benzoyl peroxide 2.5% gel.
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Stiefel, a GSK Company
Skin Quality Improvement
A Study to Evaluate the Effectiveness and Safety of Restylane Skinboosters Vital Lidocaine
This is a randomized, evaluator-blinded, no-treatment controlled, study to evaluate the effectiveness and safety of Restylane Skinboosters Vital Lidocaine treatment to improve skin quality of the face in China.
- Trial name
- NCT07047638
- Testing
- Restylane Skinboosters Vital Lidocaine
- Where
- China
- Volunteers
- 171 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Plaque Psoriasis
A Dose-Ranging Phase II Study of AUR101 in Psoriasis (INDUS-3)
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3)
- Trial name
- INDUS-3 (NCT04855721)
- Testing
- AUR101
- Where
- 25 sites in United States
- Volunteers
- 141 people
- Sponsor
- Aurigene Discovery Technologies Limited
Atopic Dermatitis
Evaluation of the Efficacy of a Cosmetic Care in Subjects With Moderate to Severe Atopic Dermatitis, Treated by Systemic Treatments
Atopic dermatitis (AD) is a common chronic inflammatory skin disease, affecting both children (15- 20%) and adults (2-5%). The pathogenesis of AD is complex and multifactorial, including skin barrier dysfunction and immune…
- Trial name
- NCT07577921
- Testing
- Investigational cosmetic product RV4427C
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Pierre Fabre Dermo Cosmetique
Skin Sensitisation
Skin Sensitization Test (Modified Draize-95 Test)
Skin Sensitization Test (Modified Draize-95) to Support a Low Dermatitis Potential Claim for a Blue Non Sterile Powder Free Nitrile Examination Gloves.
- Trial name
- Draize-95 (NCT04274647)
- Testing
- NON-STERILE, POWDER FREE NITRILE EXAMINATION GLOVES, LOW DERMATITIS POTENTIAL, TESTED FOR USE WITH CHEMOTHERAPY DRUGS - BLUE
- Where
- Malaysia
- Volunteers
- 208 people, healthy volunteers welcome
- Sponsor
- YTY Industry (Manjung) Sdn Bhd
Arthritis, Rheumatoid
Study to Evaluate the Efficacy and Safety of GSK3196165 Plus Methotrexate in Subjects With Active Moderate-Severe Rheumatoid Arthritis
This is a randomised, Phase IIb, dose-adaptive, multicentre, double-blind, parallel group, placebo-controlled study with the primary objective to assess the efficacy of GSK3196165, in combination with methotrexate (MTX), in…
- Trial name
- NCT02504671
- Testing
- GSK3196165, MTX, Folic acid
- Where
- 64 sites in Bulgaria, Canada and 12 more
- Volunteers
- 222 people
- Sponsor
- GlaxoSmithKline
Arthritis, Rheumatoid
Phase 1 Dose Escalating Study to Assess Safety, Tolerability, Food Effect and PK of CHR-5154 in Healthy Male Volunteers
Primary Objective: To determine the safety and tolerability of single and multiple ascending oral doses of CHR-5154 in healthy volunteers.
- Trial name
- NCT01934101
- Testing
- CHR-5154
- Where
- United Kingdom
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Rheumatoid Arthritis
A Study of the Effects of Oral Prednisone in Patients With Rheumatoid Arthritis (MK0000-088)
The study will compare the effects of prednisone vs placebo on synovial blood flow and overall DAS (disease activity score) in patients with rheumatoid arthritis.
- Trial name
- NCT00746512
- Testing
- Prednisone 15 mg, Prednisone 7.5 mg
- Volunteers
- 45 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Urticaria, Idiopathic, Hidradenitis
Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa
The study duration for an individual subject includes screening (14 days), the treatment period (28 days) and the observational follow-up period of 28 days, in total 70 days ± 6 days.
- Conditions
- Chronic Urticaria, Idiopathic, Hidradenitis, Hidradenitis Suppurativa
- Trial name
- NCT06555328
- Testing
- CSU lower dose treatment, CSU high dose treatment, CSU non responders IgE - high dose treatment
- Where
- 29 sites in United States, Bulgaria and 4 more
- Volunteers
- 73 people
- Sponsor
- InflaRx GmbH
Rheumatoid Arthritis
Study of SHR0302 Tablets (SHR0302) as Monotherapy in Active Rheumatoid Arthritis (RA) Patients
To evaluate the safety and efficacy of SHR0302 tablets (SHR0302) in subjects with moderate to severe active rheumatoid arthritis.
- Trial name
- NCT03254966
- Testing
- SHR0302
- Where
- China
- Volunteers
- 194 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.